Related Experiment Video
Updated: Sep 3, 2025
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
9.7K
Drug repurposing: a systematic review on root causes, barriers and facilitators
Nithya Krishnamurthy1, Alyssa A Grimshaw2, Sydney A Axson1
1Internal Medicine Department, Yale University School of Medicine, 367 Cedar Street, 4th Floor, New Haven, CT, 06520, USA.
BMC Health Services Research
|July 29, 2022
Summary
Drug repurposing shows promise but faces hurdles. Key barriers include resource limitations and intellectual property issues, while collaborations and data access facilitate success. Further research is needed to optimize this strategy.
Area of Science:
- Drug development and pharmaceutical sciences.
- Biotechnology and innovation management.
Background:
- Drug repurposing has gained traction, particularly after its use in treating COVID-19.
- Knowledge gaps exist regarding the underlying reasons, enablers, and obstacles in drug repurposing.
- A systematic review protocol was registered on Open Science Framework.
Purpose of the Study:
- To identify the reasons why companies deprioritize promising drug development.
- To explore barriers and facilitators of successful drug repurposing.
- To understand the characteristics and examples of drug repurposing.
Main Methods:
- A systematic review was conducted using multiple databases (ABI/Informa, PubMed, Scopus, Web of Science, etc.).
- Searches included controlled vocabulary and free text terms to identify relevant articles.
- 115 articles were included in the full analysis after screening 5,976 articles.
Main Results:
- The primary reasons for abandoning drugs include lack of efficacy (59), business strategies (35), and safety concerns (28).
- Key barriers to repurposing are inadequate resources (42), data access/transparency (20), and intellectual property (IP) challenges (26).
- Facilitators include multi-partner collaborations (38), access to compound databases (32), and tax incentives (2).
Conclusions:
- Drugs are often shelved due to insufficient efficacy, poor market prospects, or industry consolidation.
- Overcoming resource limitations, data access issues, and IP negotiation challenges is crucial for successful drug repurposing.
- Multi-partner collaborations, compound databases, and tax incentives are vital facilitators; further research on repurposing's value and resource support is needed.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.3K
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
10.7K
Related Concept Videos
01:26Drug Discovery: Overview
8.6K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.6K
01:25Drug Regulation
1.8K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.8K
01:03Drug Control Governance: Regulatory Bodies and Their Impact
237
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
237
01:02Prescription, Nonprescription and Orphan Drugs
838
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
838
01:19Pharmacovigilance
974
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
974
01:28Structure-Activity Relationships and Drug Design
1.0K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.0K